In addition, Compound-3 was orally active in the H460 tumor xenograft model (non-small cell lung cancer) and its cellular uptake had a low propensity to be limited by human equilibrative transporter 1 (hENT1), a nucleoside transporter that has been implied in gemcitabine transmembrane transport and certain tumor resistance [12]. Here, SLC29A1 is linked to neoplasm.